

Texas Department of State Health Services



Prevalence and Risk Factors of Diabetes Mellitus among People Living with HIV Receiving Medical Care in Texas

Sabeena Sears, MPH & Elyse J. Griffin, MPH Epidemiology and Supplemental Projects Group TB/HIV/STD Section, DSHS January 24, 2019 Cardiovascular disease (CVD) \rightarrow #1 cause of death in the US and worldwide¹



Texas Department of State Health Services

HIV therapies/immune activation/inflammations

adipose tissue changes + glucose/lipid metabolism disorders

increase CVD risk^{2,3}

Aging-related comorbidities on CVD risk poses an important health challenge among people living with HIV (PLWH)

¹Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation.* 2015;131(4):e29-322.

²Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. Journal of acquired immune deficiency syndromes 1999. 2003 Aug 1; 33(4):³Nix, L. M. & Ti506–512.

en, P. C. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr. HIV/AIDS Rep. 11, 271–278 (2014).

Type 2 Diabetes Mellitus (T2DM) is a predictor of CVD



Texas Department of State Health Services

 (T2DM) is a major risk factor for cardiovascular disease (CVD), which is the leading cause of all adult deaths in the U.S^{1,2}



¹Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes: a summary of the evidence. Diabetes care. 2005;28(7):1769-78. 2 Diagram derived from: Cardiometabolic Risk Working Group (2011) The Canadian journal of cardiology, 27 (2) PMID: 21459257

10-15% of people living with HIV have T2DM¹



Texas Department of State Health Services

• In 2017, T2DM prevalence in the US was 9.4%²

Previous 2009-10 MMP analysis found T2DM prevalence among PLWH to be 10.3% (vs. 8.3% using NHANES)¹

¹Hernandez-Romieu et al. Is diabetes prevalence higher among HIV-infected individuals? Evidence from MMP and NHANES 2009–2010. *BMJ Open Diabetes Research and Care* 2017 ²Center for Disease Control (2017): More than 100 million Americans have diabetes or prediabetes. Press release. https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html. Accessed 15 January 2019. ³Glass TR et al. Prevalence of CVD risk factors: the Swiss HIV Cohort Study. *HIV Med* 2006;7:404–10.



Study Objectives

- To estimate the prevalence of T2DM and identify risk factors among people living with HIV (PLWH) using MMP data 2013-2014
- To estimate the odds of having T2DM among PLWH by various sociodemographic characteristics such as age, sex, and race.

Methods – MMP 3-Stage Sample Design



Texas Department of State Health Services

1st Stage: states and dependent areas





Outcome – T2DM



- <u>Study sample:</u> Texas & Houston MMP Sites using 2013-2014 medical chart and interview data (N=957)
- T2DM identified by one of the of the following:
 - formal diagnosis in the medical chart
 - prescription of insulin or oral hypoglycemic medications
 - or most recent fasting blood glucose of >126 mg/dL



T2DM prevalence among PLWH higher than general population



Texas Department of State Health Services



MMP T2DM Prevalence

General population T2DM Prevalence



2/14/2019

*2015–2017 National Health and Nutrition Examination Survey (NHANES), National Center for Health Statistics, Centers for Disease Control and Prevention.

No significant differences by sex, race, smoking, and poverty with T2DM



Sex	T2DM
Male	11%
Female	12%

Poverty	T2DM
Above	10%
Below	13%

Race / Ethnicity	T2DM
White	11%
Black	11%
Hispanic	13%

Smoking	T2DM
Never	10%
Former	15%
Current	12%

BMI, age, educ. & insurance are significantly associated with T2DM



Texas Department of State Health Services

Education*	T2DM						
<hs< th=""><th>18%</th><th></th><th></th><th>Insurance*</th><th>T2DM</th></hs<>	18%			Insurance*	T2DM		
HS/equiv	10%	BWI*	T2DM	Private	5%		
>HS	10%	<25	6%	Public	18%		
Age*	T2DM	25-<30	12%	Ryan White	8%		
18-39	4%	≥30	19%	Only			
40-49	9%			Unspecified	20%		
50-59	16%			None	2%		
60+	30%						

*Statistically significant difference < 0.05

HIV Dx duration was associated with T2DM prevalence



		ViralLoad			TODM				
Duration*		(copies/ml)		TZDI	VI	Mean CD4	T2DM	
<5 years	10%	ι	Undetectable (<200)		11%			4.00/	
5-9 years	6%	(0-199	10%	
	070	≥200			12%		200-349	11%	
≥10 years	15%						100/		
			ART Use T2 Duration		2DM	M	350-499	13%	
Current	T2DM						≥500	11%	
ANT USE	44.07		<5 years	99	%				
Yes	11%		5-9 years 7%		%		*Statistically significant		
No	11%				4%				
					т70				

Age is linearly associated with diabetes likelihood



Texas Department of State Health Services



Multivariable model adjusted for age, race, birth sex, poverty, education, smoking, HIV Dx duration, CD4 count, current ART use, ART use duration, and BMI

Higher BMI → Significant odds of having diabetes



Texas Department of State Health Services



Multivariable model adjusted for age, race, birth sex, poverty, education, smoking, HIV Dx duration, CD4 count, current ART use, ART use duration, and BMI

12

No significant association of HIV-related variables with T2DM odds



Texas Department of State Health Services



HIV Dx: <5 vs. ≥10 yrs
HIV Dx: 5-9 vs. ≥10 yrs
Mean CD4: ≥500 vs. <200
Mean CD4: 350-499 vs. <200
Mean CD4: 200-349 vs. <200
Current ART use: Yes vs. No
ART use: ≥10 yrs vs. <5 yrs
ART use: 5-9 yrs vs. <5 yrs

Multivariable model adjusted for age, race, birth sex, poverty, education, smoking, HIV Dx duration, CD4 count, current ART use, ART use duration, and BMI



Conclusions

- T2DM prevalence among PLWH is slightly higher than general population
- Significant predictors: Age and BMI
- PLWH <40 had lower odds of T2DM; overweight and obese PLWH had higher odds
- Long-term data on aging PLWH needed to identify modifiable risk factors for T2DM

Implications



- Need for coordination of care between multiple providers
- Since PLWH are living longer, important to monitor age-related chronic diseases
- To improve outcomes, existing DM screening guidelines should be followed by providers
 - FBG and HbA1c obtained before and after starting ART¹
- Explore improved tests for DM Dx and monitoring
 - Diagnostic limitations of HbA1c among PLWH²

¹Aberg JA et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2014;58:1–10.

²Eckhardt B, Holzman RS, Kwan CK, et al. Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS 2012;26:197–201.



Acknowledgements

- Justin Buendia PhD, DSHS Epidemiologist
- Nallely Trejo, Texas MMP PC
- Margaret Vaaler PhD, ESP Group Manager
- Osaro Mgbere PhD, Houston MMP PC
- Data collectors
- MMP participants



Texas Department of State Health Services

Thank you!

E-mail: <u>Sabeena.Sears@dshs.texas.gov</u> <u>Elyse.Griffin@dshs.texas.gov</u>